Shinji Tsukamoto1, Piergiuseppe Tanzi2, Andreas F Mavrogenis3, Manabu Akahane4, Akira Kido5, Yasuhito Tanaka6, Marilena Cesari7, Davide Maria Donati2, Alessandra Longhi7, Costantino Errani2. 1. Department of Orthopaedic Surgery, Nara Medical University, 840, Shijo-cho, Kashihara-city, Nara, 634-8521, Japan. shinji104@mail.goo.ne.jp. 2. Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy. 3. First Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, 41 Ventouri Street, Holargos, 15562, Athens, Greece. 4. Department of Health and Welfare Services, National Institute of Public Health, 2-3-6 Minami, Wako-shi, Saitama, 351-0197, Japan. 5. Department of Rehabilitation Medicine, Nara Medical University, 840 Shijo-cho, Kashihara-city, Nara, 634-8521, Japan. 6. Department of Orthopaedic Surgery, Nara Medical University, 840, Shijo-cho, Kashihara-city, Nara, 634-8521, Japan. 7. Department of Medical Oncology, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy.
Abstract
BACKGROUND: This study compared the clinical and functional outcomes of patients initially treated with observation or medical treatment with those of patients treated with local treatment (surgery alone or surgery with adjuvant radiotherapy) to confirm whether observation or medical treatment is an appropriate first-line management approach for patients with desmoid tumors. METHODS: We retrospectively reviewed the medical records of 99 patients with histologically confirmed primary desmoid tumors treated between 1978 and 2018. The median follow-up period was 57 months. We evaluated event-free survival, defined as the time interval from the date of initial diagnosis to the date of specific change in treatment strategy or recurrence or the last follow-up. RESULTS: An event (specific change in treatment strategy or recurrence) occurred in 28 patients (28.3%). No significant difference in event-free survival was found between the first-line observation/medical treatment and local treatment groups (p = 0.509). The median Musculoskeletal Tumor Society score of the patients treated with first-line local treatment was 29 (interquartile range [IQR], 23-30), whereas that of the patients managed with first-line observation or medical treatment was 21 (IQR, 19-29.5). First-line observation or medical treatment was more frequently chosen for larger tumors (p = 0.045). In the patients treated with local treatment, local recurrence was not related to the surgical margin (p = 0.976). CONCLUSION: Upfront surgery is not advantageous compared to more conservative treatments such as observation or medical treatment for patients with desmoid tumors.
BACKGROUND: This study compared the clinical and functional outcomes of patients initially treated with observation or medical treatment with those of patients treated with local treatment (surgery alone or surgery with adjuvant radiotherapy) to confirm whether observation or medical treatment is an appropriate first-line management approach for patients with desmoid tumors. METHODS: We retrospectively reviewed the medical records of 99 patients with histologically confirmed primary desmoid tumors treated between 1978 and 2018. The median follow-up period was 57 months. We evaluated event-free survival, defined as the time interval from the date of initial diagnosis to the date of specific change in treatment strategy or recurrence or the last follow-up. RESULTS: An event (specific change in treatment strategy or recurrence) occurred in 28 patients (28.3%). No significant difference in event-free survival was found between the first-line observation/medical treatment and local treatment groups (p = 0.509). The median Musculoskeletal Tumor Society score of the patients treated with first-line local treatment was 29 (interquartile range [IQR], 23-30), whereas that of the patients managed with first-line observation or medical treatment was 21 (IQR, 19-29.5). First-line observation or medical treatment was more frequently chosen for larger tumors (p = 0.045). In the patients treated with local treatment, local recurrence was not related to the surgical margin (p = 0.976). CONCLUSION: Upfront surgery is not advantageous compared to more conservative treatments such as observation or medical treatment for patients with desmoid tumors.
Entities:
Keywords:
Active surveillance; Aggressive fibromatosis; Desmoid tumor; MSTS functional score; Surgery
Authors: Andrew J Bishop; Jace P Landry; Christina L Roland; Ravin Ratan; Barry W Feig; Bryan S Moon; Maria A Zarzour; Wei-Lien Wang; Alexander J Lazar; Valerae O Lewis; Keila E Torres; B Ashleigh Guadagnolo Journal: Cancer Date: 2020-04-28 Impact factor: 6.860
Authors: B Kasper; C Baumgarten; S Bonvalot; R Haas; F Haller; P Hohenberger; G Moreau; W T A van der Graaf; A Gronchi Journal: Eur J Cancer Date: 2014-11-27 Impact factor: 9.162
Authors: Jiwon Sarah Park; Yves-Paul Nakache; Jeremy Katz; Robert D Boutin; Robert J Steffner; Arta M Monjazeb; Robert J Canter Journal: J Surg Res Date: 2016-06-16 Impact factor: 2.192
Authors: G Duhil de Bénazé; M Vigan; N Corradini; V Minard-Colin; A Marie-Cardine; C Verite; A S Defachelles; E Thebaud; M P Castex; N Sirvent; D Bodet; L Mansuy; A Rome; A Petit; D Plantaz; A Jourdain; P Mary; M Carton; D Orbach Journal: Eur J Surg Oncol Date: 2020-02-29 Impact factor: 4.424
Authors: Michael R Cassidy; Robert A Lefkowitz; Niamh Long; Li-Xuan Qin; Amanda Kirane; Eman Sbaity; Meera Hameed; Daniel G Coit; Murray F Brennan; Samuel Singer; Aimeé M Crago Journal: Ann Surg Date: 2020-04 Impact factor: 13.787
Authors: B Kasper; C Baumgarten; J Garcia; S Bonvalot; R Haas; F Haller; P Hohenberger; N Penel; C Messiou; W T van der Graaf; A Gronchi Journal: Ann Oncol Date: 2017-10-01 Impact factor: 32.976